Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progeste...
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® ant...
Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch...
Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...
Zerion Pharma A/S announces a partnership with Aché Laboratorios Farmacêuticos S.A. (“ACHÉ”), a major Brazilian p...
Datar Cancer Genetics (DCG) has launched a revolutionary video reporting service for in vitro chemosensitivity testing, powered by AI-based technology. Thi...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...
Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitour...
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unre...
Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d...
Bristol Myers Squibb (NYSE: BMY) announced results of an analysis from the three-arm Phase 3 CheckMate -8HW trial evaluating Opdivo® (ni...
© 2025 Biopharma Boardroom. All Rights Reserved.
